LEVANIB 4 CAPSULES - LENVATINIB MESYLATE IP 4.90MG EQ. TO LENVATINIB 4MG CAPSULE

Product Description

LEVANIB 4 CAPSULES | Lenvatinib Mesylate IP 4.90mg (Equivalent to Lenvatinib 4mg Capsule)

Unlock advanced oncology care with LEVANIB 4 CAPSULES, a premium pharmaceutical formulation containing Lenvatinib Mesylate IP 4.90mg, equivalent to 4mg of Lenvatinib. Designed to deliver targeted therapeutic efficacy, this capsule is ideal for oncologists, medical distributors, and healthcare retailers focusing on high-demand cancer treatment medications.

Key Benefits:

• Targeted Cancer Therapy: Effective multi-kinase inhibitor used primarily in the treatment of thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.

• High Potency & Purity: Precisely formulated to ensure consistent bioavailability and maximum therapeutic effect.

• Trusted Composition: Manufactured under stringent GMP standards to guarantee quality and safety.

Usage:

LEVANIB 4 CAPSULES is prescribed for patients requiring advanced treatment for differentiated thyroid cancer, advanced renal cell carcinoma, and other cancers as determined by oncologists. It works by inhibiting pathways that promote tumor growth and angiogenesis.

Why Choose LEVANIB 4 CAPSULES?

• Pharma-grade Quality: Compliant with international standards, perfect for bulk procurement.

• Bulk Packaging Options: Suitable for distributors and retailers catering to hospital pharmacies and oncology centers.

• Competitive Pricing: Cost-effective solution for large-scale supply chains.